Benefits
Fewer snacking episodes than placebo (55% vs 28%)
Snacking frequency was the main secondary outcome of the 8-week trial in 60 mildly overweight women, and it fell significantly more on saffron than on placebo (P < .05). The manufacturer's published figures are a 55% drop in self-recorded snacking episodes on saffron against a 28% drop on placebo - so the placebo group improved substantially too, and the advantage is roughly 27 percentage points, not 55%. Snacking is a major contributor to caloric overconsumption, which is why it was chosen as the endpoint. This is one small manufacturer-sponsored trial and the result has not been independently replicated.
Self-reported appetite decrease (69% vs 54% on placebo)
In the same trial the supplier reports a 69% appetite decrease in the saffron group against 54% in the placebo group - a modest difference, not a 69-point advantage. The figure is subjective self-report, not measured food intake. Two other saffron trials that looked directly at appetite and craving found nothing: a 12-week trial in overweight women with mild-to-moderate depression at 30 mg/day found no significant effect on food craving, and a 6-week trial in 63 atherosclerosis patients at 100 mg/day reported that saffron did not significantly affect appetite levels.
Studied only in mildly overweight women, for 8 weeks
The published trial of this extract enrolled 60 healthy women with a BMI of 25-28, so it tells us nothing about men, about people at a higher BMI, or about use beyond 8 weeks. The manufacturer also promotes a '3x versus placebo' effect in self-identified snackers appearing within about two weeks, but that subgroup figure appears only in promotional material and is not reported in the published paper, so it should not be treated as a demonstrated result.
Stress-related overeating mechanism
The rationale for this ingredient is that saffron lifts mood and that better mood reduces stress-driven snacking. The 8-week trial did not measure mood, stress or well-being at all, so for this extract that remains a hypothesis rather than a finding. A separate 28-day randomized trial, in which 178 mg of this extract was given inside a combination supplement with naringin and vitamin D3, did measure Profile of Mood States and visual-analogue ratings and found no difference from placebo in mood, anxiety, stress or craving. What can fairly be said is that, unlike stimulant appetite suppressants, it does not carry a jitteriness or sleep-disruption burden.
Weight difference in a single 8-week trial
In the 8-week trial the saffron group lost significantly more weight than placebo (P < .01), but the trial's other anthropometric measures and vital signs remained almost unchanged, so the difference was small. Wider evidence does not support it: a 2022 meta-analysis pooling 25 randomized trials of saffron in overweight and obese people found no significant effect on body weight (-0.32 kg, p = 0.82) or BMI (-0.06 kg/m2, p = 0.91), and a 28-day randomized trial in which this same extract was given inside a combination supplement found no change in body mass, BMI or waist circumference. Any weight effect should be treated as unproven and, at best, small. This is not a thermogenic - nothing here raises caloric expenditure.
Proposed serotonergic mechanism
Serotonin signalling influences satiety, appetite and mood, and saffron constituents have shown serotonergic activity in laboratory and animal work. Serotonin has never been measured in people taking this extract, so this is a hypothesis carried over from preclinical research rather than something demonstrated in the human trials.
Widely used in consumer weight-management products
This extract appears in a number of retail appetite and 'GLP-1 support' formulas, including celebrity-branded ones. Popularity in the market is a commercial fact and says nothing about whether the ingredient works. It also does not act on GLP-1 - neither trial of this extract measured GLP-1 or any other gut hormone.
GRAS regulatory status
Saffron is listed as generally recognized as safe under 21 CFR 182.20, the list of natural extractives permitted as flavourings. That listing covers culinary use at flavouring levels; it is not a safety review of a 176.5 mg/day supplemental dose. Saffron has a long dietary history, and in the 8-week trial no participant withdrew because of the product and vital signs were unchanged.
Mechanism of action
Serotonin reuptake inhibition
The proposed primary mechanism is serotonergic activity, based on laboratory and animal studies of saffron constituents such as crocin and safranal. Serotonin signalling is involved in mood and in the brain's satiety signals, which is the basis for the idea that saffron acts on eating driven by mood rather than on metabolism. This route has not been confirmed in people taking the extract.
Stress-emotional eating circuit modulation
Stress and emotional eating share neural circuitry — chronic stress increases cortisol, which drives cravings for high-calorie palatable foods. The hypothesis is that a saffron-driven improvement in mood interrupts this cycle. Cortisol, stress and craving were not measured in the trial of this extract, and a 28-day randomized trial in which the same extract was given inside a combination supplement found no effect on self-reported stress or craving.
Satiety signal enhancement
Serotonin is a key satiety neurotransmitter — it signals fullness to the brain and reduces the drive to continue eating. The proposal is that supporting serotonin pathways nudges these satiety signals rather than blunting hunger with a stimulant. Satiety hormones and objectively measured food intake were not assessed in the trial of this extract, so this remains a proposed route rather than a measured one.
Saffron bioactive triple-compound contribution
Safranal, crocin, and picrocrocin work synergistically — safranal (volatile compound) provides the primary serotonergic effects, crocin (carotenoid) contributes antioxidant and mood support, and picrocrocin (the precursor to safranal) adds additional bioactivity. Standardizing all three compounds is intended to make batches consistent; no head-to-head trial has compared this extract with a generic saffron extract.
Non-stimulant mood and appetite mechanism
Unlike stimulant-based appetite suppressants (caffeine, ephedrine, phentermine) that work via CNS stimulation, Supresa works through serotonergic pathways. The non-stimulant mechanism avoids the side effects of stimulants (jitters, anxiety, sleep disruption, cardiovascular effects) — making Supresa suitable for daily long-term use, evening dosing, and stimulant-sensitive populations.
Clinical trials
Randomized, double-blind, placebo-controlled trial of 176.5 mg/day of this saffron stigma extract (88.25 mg twice daily) versus placebo for 8 weeks, published as Gout B, Bourges C, Paineau-Dubreuil S, Nutrition Research 2010;30(5):305-13, under the extract's European brand name Satiereal (Inoreal Ltd.). Primary outcome was body weight; the main secondary outcome was snacking frequency, self-recorded by participants in a nutrition diary. Caloric intake was left unrestricted. Sponsored by the ingredient manufacturer.
Sixty healthy, mildly overweight women with a BMI of 25-28; 31 on saffron and 29 on placebo, over 8 weeks.
Body weight fell significantly more on saffron than placebo (P < .01) and snacking frequency also fell significantly more (P < .05). Other anthropometric measures and vital signs remained almost unchanged in both groups, so the weight difference was small. The manufacturer's published figures for the same trial are a 55% drop in snacking on saffron against a 28% drop on placebo, and a 69% versus 54% split for reported appetite decrease, so the placebo group improved substantially as well. No participant withdrew because of the product. Mood and stress were not assessed. One small manufacturer-sponsored trial, not independently replicated.
Randomized, double-blind, placebo-controlled trial run at Hofstra University of a supplement containing 178 mg of this saffron extract plus 100 mg naringin and 2,000 IU vitamin D3, taken daily for 28 days. Published as Gonzalez AM, Sell KM, Ghigiarelli JJ, Spitz RW, Accetta MR, Mangine GT, Journal of Dietary Supplements 2018;15(6):965-76. Measures included body mass, BMI, waist circumference, self-reported food records, Profile of Mood States, and visual-analogue and questionnaire ratings of craving, hunger, fullness, anxiety and stress.
Twenty healthy overweight adults (mean age 25.5, mean BMI 29.9), ten on the supplement and ten on placebo, over 28 days.
No significant difference between groups in total calorie or macronutrient intake, body mass, BMI or waist circumference, and no difference in mood states, food cravings, anxiety, fullness, hunger, bloating or stress. The authors concluded the supplement produced no detectable benefit for body-weight management. Two limitations cut both ways: the study was small (20 people) and short (28 days), so it could miss a modest effect, and the saffron was given inside a combination product rather than alone.
Systematic review and meta-analysis of 25 randomized controlled trials of saffron in overweight and obese adults, published as Tahmasbi F, Araj-Khodaei M, Mahmoodpoor A, Sanaie S, Phytotherapy Research 2022;36(9):3394-3414. This is an evidence synthesis, not a clinical trial, and it pools generic saffron preparations across a range of doses rather than this specific extract.
Overweight and obese adults pooled across 25 randomized trials of various saffron preparations.
Pooling the trials showed no significant effect of saffron on body weight (-0.32 kg; 95% CI -3.15 to 2.51; p = 0.82), BMI (-0.06 kg/m2; 95% CI -1.04 to 0.93; p = 0.91), waist circumference (p = 0.41) or hip circumference (p = 0.89). Waist-to-hip ratio did fall significantly (SMD -0.41; 95% CI -0.73 to -0.09; p = 0.01). The authors described the results as promising for some cardiometabolic markers while calling for higher-quality evidence, and noted substantial heterogeneity between the pooled trials.